AFFIVANT SCIENCES HOLDINGS LIMITED

Active London

Activities of other holding companies n.e.c.

2 employees website.com
Activities of other holding companies n.e.c.
A

AFFIVANT SCIENCES HOLDINGS LIMITED

Activities of other holding companies n.e.c.

Founded 2 Sept 2020 Active London, United Kingdom 2 employees website.com
Activities of other holding companies n.e.c.

Previous Company Names

PHARMAVANT 6 HOLDINGS LIMITED 2 Sept 2020 — 23 Mar 2021
Accounts Submitted 14 Jun 2024 Next due 30 Jun 2025 11 months overdue
Confirmation Submitted 16 Sept 2024 Next due 16 Sept 2025 8 months overdue
Net assets £-28K £47K 2022 year on year
Total assets £19K £44K 2022 year on year
Total Liabilities £47K £4K 2022 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

7th Floor 50 Broadway London SW1H 0DB United Kingdom

Full company profile for AFFIVANT SCIENCES HOLDINGS LIMITED (12852351), an active company based in London, United Kingdom. Incorporated 2 Sept 2020. Activities of other holding companies n.e.c.. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2022
Type Total Exemption Full
Next accounts 31 December 2023
Due by 30 September 2024 9 months

Net Assets, Total Assets & Total Liabilities (2020–2022)

Cash in Bank

N/A

Net Assets

-£28.20k

Decreased by £47.38k (-247%)

Total Liabilities

£46.95k

Increased by £3.88k (+9%)

Turnover

N/A

Employees

2

Increased by 1 (+100%)

Debt Ratio

250%

Increased by 181 (+262%)

Financial History

Revenue, profit, EBITDA and key financial figures

2022
Dec Year End
2021
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

3 Allotments 3 Shares £120k Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
19 Sept 20241$50k$50k
31 Mar 20221$20k$20k
31 Mar 20211$50k$50k

Officers

Officers

1 active 2 resigned
Status
Emma Carys PriceDirectorBritishUnited Kingdom326 Oct 2023Active

Shareholders

Shareholders (1)

Affivant Sciences Ltd.
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active

Roivant Sciences Ltd.

Bermuda

Active
Notified 1 Oct 2021
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Group Structure

Group Structure

AFFIVANT SCIENCES HOLDINGS LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
23 Sept 2025GazetteGazette Dissolved Voluntary
8 Jul 2025GazetteGazette Notice Voluntary
26 Jun 2025DissolutionDissolution Application Strike Off Company
27 May 2025InsolvencySolvency Statement dated 13/05/25
27 May 2025CapitalStatement by Directors
23 Sept 2025 Gazette

Gazette Dissolved Voluntary

8 Jul 2025 Gazette

Gazette Notice Voluntary

26 Jun 2025 Dissolution

Dissolution Application Strike Off Company

27 May 2025 Insolvency

Solvency Statement dated 13/05/25

27 May 2025 Capital

Statement by Directors

Recent Activity

Latest Activity

Gazette Dissolved Voluntary

7 months ago on 23 Sept 2025

Gazette Notice Voluntary

10 months ago on 8 Jul 2025

Dissolution Application Strike Off Company

10 months ago on 26 Jun 2025

Solvency Statement dated 13/05/25

11 months ago on 27 May 2025

Statement by Directors

11 months ago on 27 May 2025